Related papers: Multimodal Neuroimaging Attention-Based architectu…
Neuropsychiatric symptoms (NPS) such as depression and apathy are common in Alzheimer's disease (AD) and often precede cognitive decline. NPS assessments hold promise as early detection markers due to their correlation with disease…
Alzheimer's disease (AD) is the most prevalent neurodegenerative disease; yet its currently available treatments are limited to stopping disease progression. Moreover, effectiveness of these treatments is not guaranteed due to the…
Early forecasting of individual cognitive decline in Alzheimer's disease (AD) is central to disease evaluation and management. Despite advances, it is as of yet challenging for existing methodological frameworks to integrate multimodal data…
Alzheimer's disease (AD) progresses through distinct stages, from early mild cognitive impairment (EMCI) to late mild cognitive impairment (LMCI) and eventually to AD. Accurate identification of these stages, especially distinguishing LMCI…
Early detection of Alzheimer's disease (AD) requires models capable of integrating macro-scale neuroanatomical alterations with micro-scale genetic susceptibility, yet existing multimodal approaches struggle to align these heterogeneous…
Alzheimer's disease (AD) is a progressive neurodegenerative disorder and a major cause of dementia. Structural MRI is widely used to analyze AD-related brain atrophy; however, most deep learning methods rely on computationally expensive 3D…
The ability to predict the future trajectory of a patient is a key step toward the development of therapeutics for complex diseases such as Alzheimer's disease (AD). However, most machine learning approaches developed for prediction of…
Early diagnosis of Alzheimer's disease (AD) is essential in preventing the disease's progression. Therefore, detecting AD from neuroimaging data such as structural magnetic resonance imaging (sMRI) has been a topic of intense investigation…
Background: The increasing availability of databases containing both magnetic resonance imaging (MRI) and genetic data allows researchers to utilize multimodal data to better understand the characteristics of dementia of Alzheimer's type…
Accurate diagnosis of Alzheimer's disease (AD) is both challenging and time consuming. With a systematic approach for early detection and diagnosis of AD, steps can be taken towards the treatment and prevention of the disease. This study…
Alzheimer's disease (AD) progression follows a complex continuum from normal cognition (NC) through mild cognitive impairment (MCI) to dementia, yet most deep learning approaches oversimplify this into discrete classification tasks. This…
Recent studies suggest that combined analysis of Magnetic resonance imaging~(MRI) that measures brain atrophy and positron emission tomography~(PET) that quantifies hypo-metabolism provides improved accuracy in diagnosing Alzheimer's…
Alzheimer's disease (AD), defined as an abnormal buildup of amyloid plaques and tau tangles in the brain can be diagnosed with high accuracy based on protein biomarkers via PET or CSF analysis. However, due to the invasive nature of…
Predicting future brain state from a baseline magnetic resonance image (MRI) is a central challenge in neuroimaging and has important implications for studying neurodegenerative diseases such as Alzheimer's disease (AD). Most existing…
Visualizing and interpreting convolutional neural networks (CNNs) is an important task to increase trust in automatic medical decision making systems. In this study, we train a 3D CNN to detect Alzheimer's disease based on structural MRI…
Alzheimer's disease (AD) is a neurodegenerative disorder that is beginning with amyloidosis, followed by neuronal loss and deterioration in structure, function, and cognition. The accumulation of amyloid-beta in the brain, measured through…
Alzheimer's Disease (AD) ravages the cognitive ability of more than 5 million Americans and creates an enormous strain on the health care system. This paper proposes a machine learning predictive model for AD development without medical…
Neurodegeneration as measured through magnetic resonance imaging (MRI) is recognized as a potential biomarker for diagnosing Alzheimer's disease (AD), but is generally considered less specific than amyloid or tau based biomarkers. Due to a…
The Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) is a neuropsychological tool that has been designed to assess the severity of cognitive symptoms of dementia. Personalized prediction of the changes in ADAS-Cog scores…
Diagnosing dementia, particularly for Alzheimer's Disease (AD) and frontotemporal dementia (FTD), is complex due to overlapping symptoms. While magnetic resonance imaging (MRI) and positron emission tomography (PET) data are critical for…